Vendor strategies in the global cervical cancer therapeutics market

The global cervical cancer therapeutics market is expected to grow at a CAGR of 7.08% during the forecast period. Major vendors in the global cervical cancer therapeutics market include Amgen Inc., Biocon Ltd., Cipla Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, and Pfizer Inc., among others.

Vendors are focusing on various strategies such as M&A and partnerships to enhance their reach in the market. For instance, W Amgen Inc., in January 2020, the company announced strategic collaborations with Guardant Health Inc. and QIAGEN NV to develop blood- and tissue-based companion diagnostics, respectively, for investigational cancer treatment AMG 510.

Request for: Free Sample Report

Similarly, Cipla Inc., in February 2020, the company acquired four brands of Wanbury Ltd. (Wanbury) to strengthen its presence in the women’s health segment. Dr. Reddy’s Laboratories Ltd., in February 2020, the company announced that it has entered into a definitive agreement with Wockhardt Ltd. (Wockhardt) to acquire select divisions of its branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan, and Maldives. Hence, the growing number of M&A and partnerships is expected to propel the growth of the global cervical cancer therapeutics market during the forecast period.